Chest CT scans to find prognostic signs in pulmonary mucormycosis
Official title: Chest CT Scan in Pulmonary Mucormycosis: Prognostic Value
Run by University Hospital, Strasbourg, France · NCT07339800 · Data updated 2026-11-12
This project will see if patterns on chest CT scans can predict outcomes for adults treated for pulmonary mucormycosis.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg) |
| Status | Recruiting |
| Started | September 18, 2025 |
| Main results expected | September 2026 |
| Study ends | September 19, 2026 |
| Registry record updated | January 14, 2026 |
| Trial ID | NCT07339800 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (age ≥18) treated at Strasbourg University Hospital between January 1, 2009 and June 3, 2025 with a probable or proven invasive pulmonary Mucorales infection and at least one chest CT scan.
✕Probably not a fit
Patients without thoracic CT imaging, those whose infection is not probable or proven pulmonary mucormycosis, or patients treated entirely outside Strasbourg University Hospital are unlikely to benefit from this analysis.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a retrospective observational analysis of adults with probable or proven invasive pulmonary mucormycosis treated at Strasbourg University Hospital from January 1, 2009 to June 3, 2025. Investigators will review thoracic CT scans and clinical follow-up to characterize radiological progression and correlate imaging features with clinical outcomes. The goal is to identify CT patterns associated with favorable or unfavorable courses to inform follow-up intensity and therapeutic decisions. Data interpretation will follow the 2020 EORTC/MSGERC diagnostic framework and standard radiological descriptors.
Why it matters
Potential benefit: If successful, clinicians could use specific CT patterns to tailor monitoring and treatment, potentially improving outcomes and avoiding unnecessary interventions.
How similar studies have gone: While chest imaging is established for diagnosing invasive fungal infections under the 2020 EORTC/MSGERC criteria, using CT progression patterns for prognosis is relatively novel and has limited prior evidence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged 18 years or older * Treated at Strasbourg University Hospital between January 1, 2009, and June 3, 2025 * With a diagnosis of probable or proven invasive pulmonary infection with Mucorales according to the 2020 EORTC/MSGERC criteria * Having undergone at least one CT scan including the thoracic region Exclusion Criteria: * No CT scan including the thoracic region * No diagnosis of probable or proven invasive pulmonary infection with Mucorales (EORTC/MSGERC 2020 criteria)
Where it's running
-
Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France
Strasbourg, France Recruiting
Study contacts
- Study coordinator: baptiste Hoellinger, MD
- Email: baptiste.hoellinger@chru-strasbourg.fr
- Phone: 33 3 69 55 05 45
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Patient-specific 3D-printed titanium implants for facial reconstruction
This study tests whether custom-made 3D-printed titanium facial implants can improve reconstruction and appearance for adults with facial bone defects or asymmetry.
-
Mucormycosis Clinical Core for the MUCOR-ADVANCE P01 Project
This study collects and stores blood, tissue, BAL fluid, and related data from adults with cancer who have or are at risk for mucormycosis or other fungal infections to help understand the disease.
-
Monitoring isavuconazole levels in children with invasive fungal infections
This study is testing how well isavuconazole works in children with serious fungal infections by checking their blood levels to make sure they are getting the right amount of the medicine.
-
Blood biomarkers to help diagnose invasive mucormycosis
This project will test a blood biomarker that looks for unique fungal sugars to see if it can detect invasive mucormycosis in patients with suspected infection, compared with high-risk patients without infection and patients with other fungal infections.
-
Test of a new PET tracer to detect fungal infections in adults
Researchers are testing a new PET tracer, 18F-Fluorocellobiose, to see if it helps find fungal infections in adults, including healthy volunteers and patients with invasive mold infections.
-
Liposomal Amphotericin B plus Posaconazole or Isavuconazole for Mucormycosis in Blood Cancers
This study will test whether combining IV liposomal amphotericin B with posaconazole or isavuconazole can treat mucormycosis in adults with blood cancers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.